This RSA section is an unofficial mirror, is not legal advice, and may be incomplete, outdated, or incorrectly processed.

RSA 126-Z:7 · Remote Signing

Title: X: PUBLIC HEALTH
Chapter: 126-Z · RIGHT TO TRY ACT
Status: current
Official source linked: Yes

Official source Copy section link

126-Z:7 Remote Signing. –

Copy link

Notwithstanding any regulation or provision of law to the contrary, a manufacturer of a drug, biologic, or device, a pharmacist, a health care facility, a health care provider, or a person or entity involved in the care of a patient using a drug, biologic, or device may obtain consent to treat a patient using remote signing as defined in this chapter, provided that the manufacturer, pharmacist, facility, provider, or other person or entity has an office in the state of New Hampshire and has conducted a telehealth prescreening pursuant to RSA 126-Z:1, IV. The remote signing shall amount to full and effective consent for treatment under all applicable laws and regulations.

Copy link

II.

No regulatory or law enforcement agency or subdivision shall take action against a health care facility, a health care provider, or a person or entity involved in the care of a patient for obtaining patient consent through remote signing, as defined in this chapter, if the provider or facility has complied with paragraph I.

Copy link

III.

A health care facility, a health care provider, or a person or entity involved in the care of a patient shall be immune from suit to the extent that the suit challenges the validity of a remote signing to effect lawful consent, provided that the person or entity is complying in good faith with the terms of this chapter and has not engaged in willful misconduct. Source. 2025, 304:5, eff. Jan. 1, 2026.

Copy link

Source note

Source. 2025, 304:5, eff. Jan. 1, 2026.

Source history

2025, 304:5, eff. Jan. 1, 2026

Related materials

Bill relationships

2026 HB1292 amend · effective 2027-01-01
l and qualifying severe illness. This chapter shall be construed consistently with the general court's stated purpose. 5 New Section; Regenerative Stem Cell Therapies. Amend RSA 126-Z by inserting after section 8 the following new section: 126-Z:9 Regenerative Stem Cell Therapies. I. A physician may perform stem cell therapy that is not approved by the United States Food and Drug Administrati
2026 HB1292-FN amend · effective 2027-01-01
l and qualifying severe illness. This chapter shall be construed consistently with the general court's stated purpose. 5 New Section; Regenerative Stem Cell Therapies. Amend RSA 126-Z by inserting after section 8 the following new section: 126-Z:9 Regenerative Stem Cell Therapies. I. A physician may perform stem cell therapy that is not approved by the United States Food and Drug Administrati
2026 HB1809 reference · effective 2030-11-01
ryptamine, found in certain mushrooms, but does not include synthetic or synthetic analogs of psilocybin. VI. “Qualifying patient” means a patient whom a provider, as defined by RSA 126-ZZ:1, II, has diagnosed a medically appropriate candidate for the use of medical psilocybin based on being diagnosed with a qualifying condition. VII. “Qualifying condition” means any of the following: (a) Major treat
2026 HB1809-FN reference · effective 2030-11-01
ryptamine, found in certain mushrooms, but does not include synthetic or synthetic analogs of psilocybin. VI. “Qualifying patient” means a patient whom a provider, as defined by RSA 126-ZZ:1, II, has diagnosed a medically appropriate candidate for the use of medical psilocybin based on being diagnosed with a qualifying condition. VII. “Qualifying condition” means any of the following: (a) Major treat
2026 SB504 reference · effective 2027-01-01
nt, if applicable, that patient is liable for treatment expenses; and (6) A prominent statement that the patient is seeking treatment from an experimental treatment center under RSA 126-ZZ. II. “Experimental treatment” means the provision of a medical intervention by a health care provider involving an investigational drug, biologic, or device that has successfully completed phase one of a clinical t
2026 SB504-FN reference · effective 2027-01-01
nt, if applicable, that patient is liable for treatment expenses; and (6) A prominent statement that the patient is seeking treatment from an experimental treatment center under RSA 126-ZZ. II. “Experimental treatment” means the provision of a medical intervention by a health care provider involving an investigational drug, biologic, or device that has successfully completed phase one of a clinical t
2026 SB616 amend · effective 2027-07-01
r the right to try act. Be it Enacted by the Senate and House of Representatives in General Court convened: 1 New Section; Right to Try Act; Reporting Requirement. Amend RSA 126-Z by inserting after section 8 the following new section: 126-Z:9 Reporting Requirement. I. Any health care provider providing any type of care under this chapter shall report the following information, in writing, to
2026 SB616-FN amend · effective 2027-07-01
r the right to try act. Be it Enacted by the Senate and House of Representatives in General Court convened: 1 New Section; Right to Try Act; Reporting Requirement. Amend RSA 126-Z by inserting after section 8 the following new section: 126-Z:9 Reporting Requirement. I. Any health care provider providing any type of care under this chapter shall report the following information, in writing, to